BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).

Trial Details

NCT ID
NCT07108309
Phase
PHASE2
Sponsor
Biocad
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • BCD-236
  • Chemotherapy
Locations (sample)
  • Brest, Belarus|52.10894,23.71749
  • Homyel, Belarus|52.4345,30.9754
  • Minsk, Belarus|53.90019,27.56653
  • Arkhangelsk, Russia|64.5461,40.55183
  • Barnaul, Russia|53.36199,83.72786

Key Eligibility Criteria

  • Signed informed consent and the subject's ability to comply with the requirements of the Clinical Study Protocol.
  • Age ≥18 years and \<75 years at the time of signing the informed consent form.
  • Histologically verified diagnosis (there are documented results of relevant studies) of TNBC: ER 0-2 points, PR 0-2 points or ER \<1%, PR \<1% (ASC…
  • TNBC is progressive or relapsing on or after systemic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →